UNIGE document Scientific Article
previous document  unige:94173  next document
add to browser collection

The impact of hepatitis C virus outside the liver: Evidence from Asia

Younossi, Zobair M
Tanaka, Atsushi
Eguchi, Yuichiro
Lim, Young-Suk
Yu, Ming-Lung
Kawada, Norifumi
Dan, Yock Young
Brooks-Rooney, Craig
show hidden authors show all authors [1 - 10]
Published in Liver international. 2017, vol. 37, no. 2, p. 159-172
Abstract Between 80 and 115 million people worldwide are chronically infected with hepatitis C virus, with 60%-90% of these being undiagnosed. Untreated chronic hepatitis C (CHC) is associated with progressive liver disease, cirrhosis, hepatocellular carcinoma and liver-related mortality. A number of extrahepatic manifestations are also reported in CHC patients, further adding to the burden of the disease. CHC also impacts patients in terms of lower health-related quality of life, higher levels of fatigue and reduced productivity. Furthermore, the later stages of disease are costly for both healthcare systems and society. Pegylated-interferon (PEG-IFN)+ribavirin (RBV), for many years the mainstay of treatment, leads to sustained virological response (SVR) in 40%-70% of patients. However, a substantial number of patients are ineligible for treatment, and many patients fail to achieve SVR with this regimen. Furthermore, PEG-IFN+RBV leads to impairment of patient-reported outcomes during treatment, and most patients suffer from adverse events, associated with poor adherence, treatment discontinuation and treatment failure. The approval of second-generation direct-acting antivirals (DAAs) has revolutionized the treatment of CHC patients. All-oral, PEG-IFN and RBV-free regimens have higher efficacy rates, shorter treatment durations, fewer adverse events, higher adherence rates and improvement in PROs from as early as Week 4, compared to PEG-IFN+RBV regimens. The aim of this article is to review the evidence for HCV infection as a systemic disease, summarizing the impact of hepatitis C and its treatments on clinical, patient and economic outcomes, with a focus on data from Asia and Japan specifically.
PMID: 27748564
Full text
Article (Published version) (533 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Etudes et traitement de l'hépatite C et B (554)
(ISO format)
YOUNOSSI, Zobair M et al. The impact of hepatitis C virus outside the liver: Evidence from Asia. In: Liver international, 2017, vol. 37, n° 2, p. 159-172. doi: 10.1111/liv.13272 https://archive-ouverte.unige.ch/unige:94173

333 hits

1 download


Deposited on : 2017-05-11

Export document
Format :
Citation style :